<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cerebral venous thrombosis: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cerebral venous thrombosis: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cerebral venous thrombosis: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">José M Ferro, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrícia Canhão, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cerebral venous thrombosis (CVT) is an uncommon but serious disorder. Clinical manifestations can include headache, papilledema, visual loss, focal or generalized seizures, focal neurologic deficits, confusion, altered consciousness, and coma.</p><p>Many cases have been linked to inherited and acquired thrombophilias, pregnancy, puerperium, infection, and malignancy. Infarctions due to CVT are often hemorrhagic and associated with vasogenic edema. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.)</p><p>Treatment, which is started as soon as the diagnosis is confirmed, consists of reversing the underlying cause when known, control of seizures and intracranial hypertension, and antithrombotic therapy. Anticoagulation is the mainstay of acute and subacute treatment for CVT.</p><p>This topic will review the prognosis and treatment of CVT. Other aspects of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ACUTE ANTITHROMBOTIC MANAGEMENT</span><span class="headingEndMark"> — </span>While the overall aim of treatment for CVT is to improve outcome, the immediate goals treatment for CVT are [<a href="#rid1">1-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>To recanalize the occluded sinus/vein</p><p class="bulletIndent1"><span class="glyph">●</span>To prevent the propagation of the thrombus, namely to the bridging cerebral veins</p><p class="bulletIndent1"><span class="glyph">●</span>To treat the underlying prothrombotic state, in order to prevent venous thrombosis in other parts of the body, particularly pulmonary embolism, and to prevent the recurrence of CVT</p><p></p><p>The main treatment option to achieve these goals is anticoagulation, most commonly using either heparin or low molecular weight heparin (LMWH), as discussed in the next section.</p><p class="headingAnchor" id="H3037533753"><span class="h2">Initial anticoagulation</span></p><p class="headingAnchor" id="H1196274179"><span class="h3">Management for most patients</span><span class="headingEndMark"> — </span>For most patients with CVT, we recommend anticoagulation with subcutaneous LMWH or intravenous heparin for adults with symptomatic CVT who have no contraindication.</p><p>The presence of hemorrhagic venous infarction, intracerebral hemorrhage, or isolated subarachnoid hemorrhage are not contraindications for anticoagulant treatment in CVT. The evidence summarized below (see <a class="local">'Efficacy'</a> below) suggests that subcutaneous LMWH is more effective than <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) and is at least as safe. Therefore, we prefer subcutaneous LMWH unless the patient is clinically unstable or invasive interventions such as lumbar puncture or surgery are planned or there is a contraindication to LMWH, such as kidney failure.</p><p>Treatment for children during the acute phase of CVT is similar to that for adults, but the evidence is weaker since there are no large randomized trials in this age group [<a href="#rid5">5</a>].</p><p>Treatment regimens for patients with CVT and heparin-induced thrombocytopenia (HIT) are discussed separately. (See  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p>The duration of antithrombotic treatment is reviewed below. (See <a class="local">'Long-term anticoagulation'</a> below.)</p><p class="headingAnchor" id="H4176274660"><span class="h3">Management for patients with COVID-19 vaccine-associated thrombosis</span><span class="headingEndMark"> — </span>Case series have described instances of CVT associated with thrombocytopenia in patients who are between 5 and 30 days post-vaccination with an adenovirus-vector ChAdOx1 nCov-19 (AstraZeneca COVID-19) or Ad26.COV2.S (Janssen COVID-19) vaccine [<a href="#rid6">6-11</a>].</p><p>These events are due to vaccine-induced autoantibodies against a PF4 platelet antigen, similar to those found in patients with HIT [<a href="#rid7">7</a>]. Treatment for most patients includes anticoagulation (eg, a direct oral anticoagulant, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, <a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>) and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid12">12</a>]. Platelet transfusions are typically reserved for cases of clinical relevant bleeding or preoperatively for procedures associated with a high bleeding risk (eg, neurosurgery) [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/131333.html" rel="external">"COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Thrombosis with thrombocytopenia'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Although definitive evidence of effectiveness is lacking, there is a general consensus that anticoagulation with UFH or LMWH is appropriate treatment for acute CVT, based on available data on efficacy as well as rapid onset of effect and reversibility [<a href="#rid3">3</a>]. As an example, more than 80 percent of the patients in the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) were treated with anticoagulation [<a href="#rid15">15</a>].</p><p>Two randomized controlled trials of anticoagulation in acute CVT  (<a class="graphic graphic_table graphicRef69484" href="/d/graphic/69484.html" rel="external">table 1</a>) have been published [<a href="#rid1">1,16</a>]. Both have methodologic problems, most importantly their modest sample size.</p><p class="bulletIndent1"><span class="glyph">●</span>The Berlin trial of intravenous heparin versus placebo was stopped prematurely because of excess mortality in the placebo arm [<a href="#rid16">16</a>]. Patients randomized to the heparin arm had significantly better outcomes on a nonvalidated composite CVT severity scale than those in the placebo group. The average length from onset of symptoms to anticoagulation treatment, four weeks, was exceptionally long.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Dutch trial of subcutaneous <a class="drug drug_general" data-topicid="10060" href="/d/drug information/10060.html" rel="external">nadroparin</a> versus placebo enrolled 60 patients but excluded those who needed lumbar punctures for the relief of increased intracranial pressure [<a href="#rid1">1</a>]. More patients treated with LMWH followed by oral anticoagulation had a favorable outcome than controls, but the difference between the groups was not statistically significant  (<a class="graphic graphic_table graphicRef69484" href="/d/graphic/69484.html" rel="external">table 1</a>). Despite randomization, an imbalance at baseline may have favored the placebo group, as there were more cases with isolated intracranial hypertension in the placebo group and more patients with infarcts in the nadroparin group.</p><p></p><p>A meta-analysis of these two trials found that anticoagulant treatment compared with placebo was associated with a pooled relative risk of death of 0.33 (95% CI 0.08-1.21) and a risk of death or dependency of 0.46 (95% CI 0.16-1.31) [<a href="#rid17">17</a>]. While these data suggest that anticoagulant treatment for CVT may be associated with a reduced risk of death or dependency, the results did not achieve statistical significance.</p><p>Limited data suggest that LMWH is more effective than UFH and at least as safe for the treatment of CVT:</p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label trial, 66 adults with CVT were randomly assigned to treatment with LMWH or UFH [<a href="#rid18">18</a>]. In-hospital mortality was significantly lower in the LMWH group (0 versus 19 percent). At three months, the proportion of patients with complete recovery was greater for the LMWH group (88 versus 63 percent), but the difference was not statistically significant. Small numbers limit the strength of these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a nonrandomized case-control study, a greater proportion of adult patients treated with LMWH (n = 119) compared with UFH (n = 302) were independent at six months (92 versus 84 percent; adjusted odds ratio 2.4, 95% CI 1.0-5.7) [<a href="#rid19">19</a>]. Treatment with LMWH was also associated with slightly lower rates of mortality (6 versus 8 percent) and new intracranial hemorrhage (10 versus 16 percent), but these outcomes were not statistically significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center double-blind trial conducted in Iran, 52 cases of CVT were randomly assigned to treatment with LMWH or UFH. There was no difference between the treatment groups in neurological deficits, disability, and mortality [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H3155170373"><span class="h3">Risk of new intracranial hemorrhage</span><span class="headingEndMark"> — </span>Anticoagulants appear to be safe to use in adult patients with CVT who have associated intracranial hemorrhage, either intracerebral (such as hemorrhagic venous infarction) or subarachnoid [<a href="#rid21">21</a>]. In the Berlin and Dutch trials, 34 of 79 patients (43 percent) had an intracerebral hemorrhage at baseline [<a href="#rid1">1,16</a>]. None of the patients randomized to heparin developed a new intracerebral hemorrhage. In contrast, a new intracerebral hemorrhage developed in three patients randomized to placebo. Case series have also reported relatively low risks of intracranial hemorrhage (&lt;5 percent) and systemic hemorrhage (&lt;2 percent), and such hemorrhages did not influence outcome [<a href="#rid22">22-25</a>]. These findings are in accordance with the hypothesis that hemorrhage in CVT is caused by the probable mechanism of venous outflow blockage and very high intradural and intravenous pressure, leading to both rupture of venules and to hemorrhagic transformation of venous infarctions.</p><p>Similarly, observational data from case series and subgroup analyses of controlled trials suggest that anticoagulant therapy is safe in children with CVT [<a href="#rid5">5,26-32</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Endovascular treatment</span><span class="headingEndMark"> — </span>For selected adults and children with CVT who develop progressive neurologic worsening despite adequate anticoagulation with subcutaneous LMWH or intravenous heparin, endovascular thrombolysis or mechanical thrombectomy may be a treatment option at centers experienced with these methods.</p><p>The potential utility of endovascular treatment was described in a 2015 systematic review that identified 42 studies and 185 patients with CVT who were treated with mechanical thrombectomy [<a href="#rid33">33</a>]. Many of the patients were severely ill; pretreatment intracerebral hemorrhage was present in 60 percent and stupor or coma in 47 percent. A variety of devices were used, including the AngioJet rheolytic catheter, balloon angioplasty, stents, and microsnares; concurrent local thrombolysis was used in 71 percent. Overall, a good outcome was reported for 84 percent of patients; mortality was 12 percent. New or worsened intracerebral hemorrhage affected 10 percent. A high recanalization rate (95 percent; 21 percent partial) was achieved.</p><p>However, a randomized controlled trial (TO-ACT) [<a href="#rid34">34</a>] failed to show benefit of endovascular treatment (thrombectomy with or without chemical thrombolysis) over anticoagulation in patients with acute CVT and at least one risk factor for clinical deterioration (coma, mental status disturbance, CVT involving the deep venous system, intracerebral hemorrhage). However, as the trial had a modest sample size and was prematurely stopped for futility, the possibility of a small treatment effect in some patients cannot be excluded.</p><p>Among nearly 50,000 patients with CVT from the United States Nationwide Inpatient Sample 2004 to 2014, mortality was higher for patients with CVT treated with endovascular approaches than medical therapy with anticoagulation, even after adjusting for age, severity of symptoms, and the burden of complications (eg, intracranial hemorrhage, venous infarction, and cerebral edema; odds ratio 1.96, 95% CI 1.6-3.3) [<a href="#rid35">35</a>]. In addition, a 2010 systematic review of 15 studies including 156 patients revealed that despite endovascular treatment, there is a death rate of 9 percent and that local thrombolysis is complicated by a non-negligible rate of major bleeding (10 percent), including 8 percent intracranial hemorrhages, 58 percent of which were fatal [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Guideline recommendations</span><span class="headingEndMark"> — </span>Consensus guidelines support the use of anticoagulation for the acute treatment of CVT in adults and children.</p><p>Guidelines for acute treatment in adults include:</p><p class="bulletIndent1"><span class="glyph">●</span>The 2017 European Stroke Organization guidelines for the diagnosis and treatment of cerebral venous thrombosis, endorsed by the European Academy of Neurology, recommend heparin at therapeutic dosage to treat adult patients with acute CVT, including those with an intracerebral hemorrhage at baseline [<a href="#rid37">37</a>]. The guidelines suggest using LMWH instead of UFH. No recommendation is made regarding thrombolysis for acute CVT, except that patients who have a pretreatment low risk of poor outcome (eg, absence of coma, mental status disturbance, thrombosis of the deep venous system, intracranial hemorrhage, and malignancy) should not be exposed to aggressive treatments such as thrombolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2014 American Heart Association (AHA)/American Stroke Association (ASA) guidelines for the prevention of stroke state that anticoagulation is reasonable for patients with acute CVT, even in selected patients with intracranial hemorrhage [<a href="#rid38">38</a>]. The 2011 AHA/ASA guidelines for the diagnosis and management of CVT conclude that initial anticoagulation with adjusted-dose UFH or weight-based LMWH in full anticoagulant doses is reasonable, followed by vitamin K antagonists, regardless of the presence of intracerebral hemorrhage [<a href="#rid39">39</a>].</p><p></p><p>Guidelines for acute treatment in children include:</p><p class="bulletIndent1"><span class="glyph">●</span>The 2012 American Academy of Chest Physicians (ACCP) guidelines recommends initial anticoagulation with UFH or LMWH, followed by LMWH or vitamin K antagonist treatment (ie, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) for a minimum of three months for children with CVT but without significant intracerebral hemorrhage [<a href="#rid40">40</a>]. Anticoagulation for an additional three months is suggested if there is still cerebral sinovenous occlusion or ongoing symptoms (the latter presumably meaning new venous infarcts or increased intracranial pressure) after three months of therapy.</p><p></p><p class="bulletIndent1">For children with CVT who have significant intracerebral hemorrhage, the ACCP suggests either initial anticoagulation as for children without hemorrhage or radiologic monitoring of the thrombosis at five to seven days and anticoagulation if thrombus extension is noted at that time [<a href="#rid40">40</a>]. The ACCP suggests thrombolysis, thrombectomy, or surgical decompression only in children with severe CVT in whom there is no improvement with initial anticoagulation therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2019 AHA/ASA scientific statement for the management of stroke in neonates and children endorses anticoagulation for children with CVT [<a href="#rid41">41</a>]. Antithrombotic selection should be individualized, guided by patient circumstances, and informed by a multidisciplinary consensus approach particularly when CVT is associated with hemorrhagic infarction, otitis media/mastoiditis, head trauma, or cranial surgery. Surveillance vascular neuroimaging is recommended to guide the duration of anticoagulation. Endovascular intervention is an option for rare circumstances when there is sudden clinical deterioration or a high risk of mortality.</p><p></p><p class="bulletIndent1">For neonatal patients with CVT, anticoagulation with LMWH or heparin may be considered, particularly those with clinical deterioration or evidence of thrombus extension on serial imaging [<a href="#rid41">41</a>]. Serial imaging at five to seven days should be considered to exclude propagation when a decision is made not to be anticoagulated.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">OTHER ACUTE MANAGEMENT ISSUES</span><span class="headingEndMark"> — </span>Major problems that may require intervention in the acute phase of CVT include elevated intracranial pressure, brain swelling, and seizures.</p><p class="headingAnchor" id="H13"><span class="h2">Elevated intracranial pressure and herniation</span><span class="headingEndMark"> — </span>In the acute phase, elevated intracranial pressure (ICP) may arise from single or multiple large hemorrhagic lesions, infarcts, or brain edema. Elevated ICP or space-occupying lesions may cause transtentorial herniation and death.</p><p class="bulletIndent1"><span class="glyph">●</span>General recommendations to control acutely elevated ICP should be followed, including elevating the head of the bed, intensive care unit admission, mild sedation as needed, administering osmotic therapy (<a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>), hyperventilation to a target partial pressure of carbon dioxide (PaCO<sub>2</sub>) of 30 to 35 mmHg, and ICP monitoring [<a href="#rid21">21,42</a>]. (See  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults"</a> and  <a class="medical medical_review" href="/d/html/6077.html" rel="external">"Elevated intracranial pressure (ICP) in children: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with impending herniation due to unilateral hemispheric lesion, hemicraniectomy can be lifesaving. Retrospective data from a registry and systematic reviews suggest that death can be prevented and a good functional outcome can be achieved [<a href="#rid43">43,44</a>].</p><p></p><p>There is no good evidence to support ventricular shunting as a treatment for acute hydrocephalus or impending brain herniation in the acute phase of CVT [<a href="#rid45">45</a>].</p><p>In patients with sustained ICP elevation, successful treatment of intracranial hypertension can prevent visual failure and resolve headache. A prospective study in 59 patients with CVT presenting with isolated intracranial hypertension noted a complete recovery in over 90 percent [<a href="#rid46">46</a>]; patients had a variety of interventions, and most had a therapeutic lumbar puncture (LP). However, there are no studies specifically evaluating therapeutic LP for elevated ICP or isolated intracranial hypertension in patients with CVT. Data from the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) did not show differences in the outcomes in patients who had diagnostic LP [<a href="#rid15">15</a>]. European guidelines state that therapeutic LP may be considered in patients with CVT and signs of intracranial hypertension, because of a potential beneficial effect on visual loss and/or headache, whenever its safety profile is acceptable [<a href="#rid37">37</a>].</p><p>Although glucocorticoids, in particular intravenous <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, are prescribed in many centers, they are not recommended for treating CVT in the absence of an underlying inflammatory disorder such as Behçet disease or systemic lupus erythematosus [<a href="#rid37">37,47-49</a>]. No randomized clinical trials have been performed to evaluate their efficacy for CVT, but available evidence suggests they are ineffective. This conclusion is supported by a study that analyzed data from the observational ISCVT cohort of 642 patients with CVT (including 150 patients treated with glucocorticoids) using case-control methods that failed to demonstrate any benefit of glucocorticoids, even for patients with parenchymal lesions [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>For patients with CVT who have both seizures and focal cerebral supratentorial lesions such as edema or infarction on admission head computed tomography (CT) or brain magnetic resonance imaging (MRI) lesions, we recommend seizure prophylaxis with antiseizure medication.</p><p>In patients with CVT, recurrent seizures are more likely to develop in those who present with seizures and in those with supratentorial brain lesions (focal edema or ischemic or hemorrhagic infarcts) on admission brain imaging [<a href="#rid51">51</a>]. The risk of developing seizures after CVT diagnosis is very low in patients who do not have these risk factors. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'Seizures'</a>.)</p><p>Data are limited regarding the effectiveness of seizure prophylaxis with antiseizure medications in patients with CVT [<a href="#rid21">21,52</a>]. In the ISCVT cohort, early seizures (those occurring within two weeks after CVT diagnosis) were observed in the following patient subgroups, comparing those not treated with antiseizure medication versus those treated with antiseizure medication [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with no supratentorial lesion and no seizure at presentation, early seizure occurred in 5 of 197 (2.5 percent) not on antiseizure medications versus 0 of 11 (0 percent) on antiseizure medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In those with no supratentorial lesion who presented with seizure, early seizures occurred in 1 of 14 (7 percent) not on antiseizure medications and 0 of 35 (0 percent) on antiseizure medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a supratentorial lesion but no seizure at presentation, early seizures occurred in 11 of 134 (8 percent) not on antiseizure medications and 1 of 35 (3 percent) on antiseizure medications (odds ratio [OR] 0.3, 95% CI 0.04-2.6).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a supratentorial lesion who presented with seizure, early seizures occurred in 24 of 47 (51 percent) not on antiseizure medications and 1 of 148 (&lt;1 percent) on antiseizure medications (OR 0.006, 95% CI 0.001-0.05).</p><p></p><p>Thus, antiseizure medications prophylaxis appears to be associated with a reduced risk of early seizures in patients with CVT. The risk reduction was statistically significant for patients in the highest risk group (those with a supratentorial lesion and seizure at presentation) [<a href="#rid51">51</a>]. The strength of this study is limited by its observational and retrospective design, but it represents the largest experience in the literature.</p><p>Based upon these data, we recommend seizure prophylaxis only for patients with both seizures at presentation and supratentorial lesions such as edema, infarction, or hemorrhage on admission head CT or brain MRI. Prophylaxis is not clearly required for a single early symptomatic seizure with CVT in the absence of supratentorial lesion, as there is often no seizure recurrence. Furthermore, seizure prophylaxis is not recommended for patients who have focal cerebral lesions without seizures [<a href="#rid37">37,39</a>].</p><p>When antiseizure medication prophylaxis is used, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is preferable to <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> because they have fewer pharmacologic interactions with oral vitamin K antagonist anticoagulants (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) [<a href="#rid53">53</a>]. General recommendations for the selection of antiseizure medications are discussed separately. (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Antiseizure medication therapy'</a> and  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Selection of an antiseizure medication'</a>.)</p><p>The duration of antiseizure medication therapy is discussed separately (See <a class="local">'Seizure prevention'</a> below.)</p><p class="headingAnchor" id="H2969700175"><span class="h2">Infection and inflammation</span><span class="headingEndMark"> — </span>Antibiotic treatment is mandatory whenever there is meningitis or other intracranial infection or an infection of a neighboring structure, such as otitis or mastoiditis. For associated inflammatory diseases such as Behçet disease, lupus, or vasculitis, treatment with glucocorticoids may be necessary.</p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT AFTER THE ACUTE PHASE</span><span class="headingEndMark"> — </span>The subacute phase of CVT often involves decisions regarding the duration of anticoagulation and antiseizure medication use. In addition, there may be long-term complications including headaches, visual loss, cognitive impairment, and psychiatric disturbances.</p><p class="headingAnchor" id="H16"><span class="h2">Long-term anticoagulation</span><span class="headingEndMark"> — </span>The aim of continuing anticoagulation after the acute phase is to prevent CVT recurrence, which affects 2 to 7 percent of patients, and to prevent extracerebral venous thrombosis, which occurs in up to 5 percent of patients with CVT, mainly from deep venous thrombosis of the limbs or pelvis, and/or pulmonary embolism [<a href="#rid15">15</a>]. (See <a class="local">'Recurrence'</a> below.)</p><p class="headingAnchor" id="H787853191"><span class="h3">Selection of anticoagulant</span><span class="headingEndMark"> — </span>For most adults with CVT, we suggest anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or a direct oral anticoagulant after the acute phase. Direct oral anticoagulants may be preferable for most patients, based upon the lower burden of blood monitoring and dose adjustments, fewer drug interactions, and lack of dietary restrictions when compared with warfarin. When warfarin is used, the dose should be adjusted to an international normalized ratio (INR) target of 2.5 (acceptable range: 2 to 3).</p><p>Although high-quality evidence is limited, either <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or a direct oral anticoagulant appears to be safe and effective to prevent recurrent CVT and other forms of venous thromboembolism (VTE) in patients with CVT. A systematic review of 19 studies that included nearly 2000 patients with CVT found rates of recurrent thromboembolism and intracranial hemorrhage were similar for patients treated with vitamin K antagonists or direct oral anticoagulants [<a href="#rid54">54</a>]. However, certainty of the data is limited by the observational nature of many of the included studies, risk of selection and treatment biases, as well as varied outcome parameters. In the open-label RE-SPECT CVT trial, 120 patients with CVT of mild to moderate severity were randomly assigned to <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> (150 mg twice daily) or warfarin (titrated to a target INR of 2 to 3) for a period of 24 weeks [<a href="#rid55">55</a>]. Patients with coma, major trauma, central nervous system infections, or active cancer were excluded. During the study period, there were no recurrent venous thromboembolic events in either treatment group. Major bleeding was limited to intestinal bleeding in one patient assigned to dabigatran and subdural hemorrhages in two patients assigned to warfarin. European guidelines, which were published in 2017 prior to the RE-SPECT CVT trial, do not recommend using direct oral anticoagulants for the prevention of recurrent venous thrombosis after CVT [<a href="#rid37">37</a>].</p><p>In the retrospective ACTION-CVT observational study that included 845 anticoagulated patients with CVT of mild to moderate severity, clinical and radiographic outcomes were assessed at a median follow-up of 345 days for patients treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (52 percent), a direct oral anticoagulant (33 percent), or both at different times (15 percent) [<a href="#rid56">56</a>]. Patients with CVT associated with pregnancy, antiphospholipid syndrome, and cancer were excluded. Compared with warfarin, treatment with a direct oral anticoagulant was associated with similar risks of recurrent venous thrombosis and death, as well as similar rates of recanalization on follow-up imaging. In addition, treatment with a direct oral anticoagulant was associated with a lower risk of major hemorrhage (adjusted hazard ratio 0.35, 95% CI 0.15-0.82).</p><p>Special populations of patients with CVT require a different approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – For patients with malignancy who require long-term anticoagulation and who do not have chronic kidney failure (creatinine clearance &lt;30 mL/minute), low molecular weight heparin (LMWH) is generally preferred rather than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or direct oral anticoagulants, but oral anticoagulation is preferred over no therapy. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome</strong> – For patients with an antiphospholipid antibody syndrome and CVT, clinical efficacy and safety data suggest <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is preferred over direct oral anticoagulants. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney failure</strong> – Patients with severe chronic kidney failure should not receive direct oral anticoagulants; vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) are preferred for oral therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – For most patients who require long-term anticoagulation during pregnancy (with the exception of patients with mechanical heart valves), heparins are safer than other anticoagulants. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and direct oral anticoagulants are contraindicated. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – Several anticoagulants have been used for children with CVT including vitamin K antagonists, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, or LMWH [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a> or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> can also be used to prevent recurrent venous thrombotic events after acute CVT, depending on patient and parent preferences and drug and dietary interactions.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a> was compared with standard anticoagulation (LMWH or vitamin K antagonist) in children with CVT in an exploratory substudy [<a href="#rid57">57</a>] of the open-label EINSTEIN-Jr trial [<a href="#rid58">58</a>], which assigned patients with VTE to bodyweight-adjusted rivaroxaban 20 mg equivalent dose or standard anticoagulation for a period of three months. Partial or complete recanalization rates were similar in both groups and occurred in roughly 75 percent. There was one recurrent VTE (in a child assigned to standard anticoagulation). One subdural hematoma occurred among children assigned to standard anticoagulation (n = 41) and five clinically relevant (nonmajor extracranial) bleeding events in those who received rivaroxaban (n = 73). A subgroup analysis of the EINSTEIN-Jr trial, including children with CVT and an associated head or neck infection administered therapeutic anticoagulants, showed that generally they had low risks of bleeding and thrombotic complications, including those who had surgical interventions with delay or interruption of anticoagulation [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">In a subgroup analysis of the DIVERSITY trial, a single-arm trial of <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> in children with VTE, few children with CVT developed recurrent VTE or experienced major or clinically relevant nonmajor bleeding when receiving prophylaxis with dabigatran [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H1032541849"><span class="h3">Duration of anticoagulation</span><span class="headingEndMark"> — </span>After the acute phase of CVT, we suggest continuing anticoagulation for a minimum period of three months and up to 12 months. However, there is no definitive evidence regarding the optimal duration of anticoagulant therapy specifically for reducing the risk of recurrent CVT [<a href="#rid37">37</a>]. A reasonable approach may be to stratify the duration of anticoagulant therapy according to the individual prothrombotic risk as follows [<a href="#rid39">39,61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a provoked CVT associated with a transient risk factor  (<a class="graphic graphic_table graphicRef65303" href="/d/graphic/65303.html" rel="external">table 2</a>), anticoagulation is continued for three to six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an unprovoked CVT, anticoagulation is continued for 6 to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with recurrent CVT, VTE after CVT, or a first CVT with a severe thrombophilia (ie, homozygous prothrombin gene <em>G20210A</em> variant, homozygous factor V Leiden genetic variant, deficiencies of protein C, protein S, or antithrombin, combined thrombophilia defects, or antiphospholipid syndrome), anticoagulation may be continued indefinitely.</p><p></p><p class="headingAnchor" id="H2847729407"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span>We generally do <strong>not</strong> use <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or other antiplatelet medications for long-term management of patients after CVT, unless a separate indication for therapy is present. The benefit of aspirin or other antiplatelet agents after CVT has not been established in controlled trials or observational studies, and current guidelines make no recommendation about aspirin in this setting [<a href="#rid37">37,39</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Seizure prevention</span><span class="headingEndMark"> — </span>Patients who experience a seizure after a hemispheric CVT are typically started on antiseizure medication treatment, while patients who do not are generally not started on antiseizure medication prophylaxis. (See <a class="local">'Seizures'</a> above.)</p><p>The optimal duration of antiseizure medication treatment after CVT is unknown. For patients with CVT and associated parenchymal brain lesions who present with one or more seizures in the acute phase, antiseizure medications should be continued until seizure-free for a defined duration (eg, one year).</p><p>The risk of epilepsy after CVT ranges from 5 to 11 percent of patients [<a href="#rid15">15,62-64</a>]. The risk is higher in those with seizures in the acute phase, with hemorrhagic parenchymal lesions, and who survived a decompressive hemicraniectomy [<a href="#rid63">63,64</a>]. Late-onset seizures indicate an even higher risk of epilepsy. In one study of 123 CVT patients with late seizures (occurring more than seven days after CVT diagnosis), 70 percent had a recurrent seizure during a mean two-year follow-up [<a href="#rid64">64</a>].</p><p>General recommendations for the selection and withdrawal of antiseizure medications are discussed separately. (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Antiseizure medication therapy'</a> and  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Discontinuing antiseizure medication therapy'</a> and  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Selection of an antiseizure medication'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Headaches</span><span class="headingEndMark"> — </span>Chronic headaches have been reported to occur in more than half of patients with prior CVT [<a href="#rid65">65</a>]. Headaches severe enough to require bed rest or hospital admission afflict 14 percent of patients with CVT [<a href="#rid15">15</a>]. Repeated brain MRI and magnetic resonance venography (MRV) are necessary to exclude the rare case of recurrent CVT. MRV may depict stenosis of a previously occluded sinus [<a href="#rid66">66,67</a>].</p><p>Lumbar puncture may be necessary to exclude chronically elevated intracranial pressure (ICP) if headache persists and brain MRI and MRV are normal. In such cases, therapeutic options to treat elevated ICP include <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> (500 mg twice daily) or <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> (for patients who cannot tolerate acetazolamide), but efficacy is unproven [<a href="#rid39">39</a>]. Additional options if severe headache associated with increased intracranial hypertension persists include repeated lumbar punctures, a lumboperitoneal shunt, or stenting of sinus stenosis [<a href="#rid68">68-70</a>], but efficacy after CVT is also unproven.</p><p class="headingAnchor" id="H19"><span class="h2">Visual loss</span><span class="headingEndMark"> — </span>Severe visual loss due to CVT is fortunately a rare event [<a href="#rid71">71-73</a>]. Nevertheless, elevated intracranial pressure must be rapidly ruled out and managed accordingly if visual acuity decreases during follow-up and is not explained by ocular causes. Fenestration of the optic nerve sheath has also been used to relieve pressure and prevent optic nerve atrophy, but efficacy is not established [<a href="#rid39">39,74</a>].</p><p>Because of the potential for visual loss caused by severe or long-standing elevation of intracranial pressure, serial assessment of visual fields and visual acuity is recommended for children with CVT during follow-up, particularly during the first year [<a href="#rid39">39,42</a>]. It is reasonable to do the same for adults with visual complaints, chronic headaches, or papilledema.</p><p class="headingAnchor" id="H20"><span class="h2">Cognitive and psychiatric complications</span><span class="headingEndMark"> — </span>Despite the apparent general good recovery in most patients with CVT, approximately one-half of the survivors feel depressed or anxious, and minor cognitive or language deficits may preclude them from resuming their previous jobs [<a href="#rid75">75,76</a>]. Patients should be reassured of the very low level of risk of recurrence of CVT and be encouraged to return to previous occupations and hobbies. In some cases, antidepressants may be necessary.</p><p class="headingAnchor" id="H21"><span class="h2">Subsequent pregnancy</span><span class="headingEndMark"> — </span>We suggest prophylaxis with LMWH during pregnancy and puerperium for those with a previous history of CVT to reduce the risk of recurrent CVT and other venous thromboembolic events, in accord with guidelines from the European Stroke Organization and the American Heart Association/American Stroke Association [<a href="#rid37">37,39,77</a>].</p><p>For pregnant patients with a history of CVT, we suggest temporary prophylactic anticoagulation with subcutaneous LMWH throughout pregnancy and continuing up to eight weeks postpartum. (See  <a class="medical medical_review" href="/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>.)</p><p>Pregnancy and the puerperium are known risk factors for CVT (see  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'Risk factors and associated conditions'</a>). The absolute risk of complications during subsequent pregnancy among those who have a history of CVT appears to be low, although the relative risks of recurrent CVT and noncerebral VTE are quite elevated compared with the general population. Supporting evidence comes from a 2016 systematic review of 13 observational studies evaluating the frequency of CVT or noncerebral VTE associated with pregnancy and the puerperium in those with a history of previous CVT [<a href="#rid78">78</a>]. The following observations were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent CVT occurred in 2 of 217 pregnancies (9 per 1000 pregnancies, 95% CI 3-33 per 1000), a rate that was more than 80-fold higher than the previously reported incidence in the general population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncerebral VTE occurred in 5 of 186 pregnancies (27 per 1000, 95% CI 12-61 per 1000), a rate that was approximately 16-fold higher than the incidence previously described in the general population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous abortion occurred in 33 of 186 pregnancies (18 percent, 95% CI 13-24 percent), a rate similar to the estimated rate in the general population. (See  <a class="medical medical_review" href="/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology", section on 'Incidence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no significant difference in the rate of spontaneous abortion for patients treated or not treated with antithrombotic therapy (11 versus 19 percent).</p><p></p><p>Thus, based upon the available evidence, a history of CVT, including pregnancy- or puerperium-related CVT, is not a contraindication for future pregnancy.</p><p>Patients should be advised not to become pregnant while on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> because of its teratogenic effects and increased risk of fetal bleeding. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Already taking warfarin'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Oral contraceptives</span><span class="headingEndMark"> — </span>Because it is a risk factor for CVT, female patients with prior CVT should be informed about the risks of combined estrogen-progestin hormonal contraception and advised against its use [<a href="#rid37">37,42</a>]. Risk is associated with the dose of ethinyl estradiol (less risk with doses &lt;50 mcg). The type of progestin is also associated with VTE risk; in general, the lowest risk is seen with combined oral contraceptives that contain a second-generation progestin such as <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a>. These risks are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'</a>.)</p><p class="headingAnchor" id="H2654869574"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>CVT can result in death or permanent disability but usually has a favorable prognosis.</p><p class="headingAnchor" id="H3026814022"><span class="h2">Early deterioration and death</span><span class="headingEndMark"> — </span>Approximately 5 percent of patients die in the acute phase of the disorder [<a href="#rid79">79,80</a>]. Most of the early deaths are a consequence of CVT. A systematic review found that mortality rates among patients with CVT declined since the 1960s; increased detection of less severe cases with advances in neuroimaging along with improved hospital care may have accounted for some or all of the decreased mortality [<a href="#rid81">81</a>].</p><p>In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) that evaluated 624 patients (age &gt;15 years) with CVT, 27 patients (4.3 percent) died during hospitalization for the acute phase, including 21 patients (3.4 percent) who died within 30 days from symptom onset [<a href="#rid79">79</a>].</p><p>Predictors of mortality at 30 days in the ISCVT were as follows [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Depressed consciousness</p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis of the deep venous system</p><p class="bulletIndent1"><span class="glyph">●</span>Right hemisphere hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Posterior fossa lesions</p><p></p><p>Early mortality in children with CVT is similar to that in adults. In a European cohort of 396 children with CVT (median age 5.2 years), death in the first two weeks after presentation occurred in 12 patients (3 percent) [<a href="#rid82">82</a>].</p><p>The main cause of acute death with CVT is transtentorial herniation secondary to a large hemorrhagic lesion [<a href="#rid79">79</a>]. Other causes of early death include herniation due to multiple lesions or to diffuse brain edema, status epilepticus, medical complications, and pulmonary embolism [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1043328316"><span class="h2">Long-term outcome</span><span class="headingEndMark"> — </span>Mortality after the acute phase of CVT is predominantly related to underlying conditions. The main ISCVT report [<a href="#rid15">15</a>] performed a meta-analysis of seven prospective series and found that acute CVT was associated with a 15 percent overall death or dependency rate at the end of follow-up, which varied from 3 to 78 months.</p><p>In the ISCVT study, complete recovery at the end of follow-up (median 16 months) was noted in 79 percent of the entire cohort of patients, while death was the outcome in 8 percent [<a href="#rid15">15</a>].</p><p>Predictors of poor long-term prognosis in the ISCVT were as follows [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system infection</p><p class="bulletIndent1"><span class="glyph">●</span>Any malignancy</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis of the deep venous system</p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhage on head CT or MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Glasgow coma scale score &lt;9 on admission  (<a class="graphic graphic_table graphicRef59662" href="/d/graphic/59662.html" rel="external">table 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Mental status abnormality</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;37 years</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p></p><p>The CVT risk score was designed to estimate the functional prognosis at six months after CVT onset; the score was derived using data from the original ISCVT cohort of 624 patients and validated in two smaller cohorts [<a href="#rid83">83</a>]. The score is tallied as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of malignancy – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Coma on admission – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis involving the deep venous system – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Mental status disturbance on admission – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Intracranial hemorrhage on admission – 1 point</p><p></p><p>A CVT risk score ≥3 was associated with a poor outcome, defined as a modified Rankin Scale  (<a class="graphic graphic_table graphicRef75411" href="/d/graphic/75411.html" rel="external">table 4</a>) score of &gt;2 (dependency or death), with a high sensitivity but poor specificity (96 and 14 percent, respectively) [<a href="#rid83">83</a>].</p><p>In the ISCVT, complete recovery at six months was significantly more common for female than male patients (81 versus 71 percent), while dependency or death was less likely for females than males (12 versus 20 percent) [<a href="#rid84">84</a>]. These differences were driven entirely by the more favorable outcome for the subgroup of females who had sex-specific risk factors (mainly oral contraceptives, pregnancy, or puerperium) for CVT. Females without sex-specific risk factors had outcomes similar to males. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'Epidemiology'</a>.)</p><p>Intracerebral hemorrhage present at the time of CVT diagnosis was identified in 245 patients (39 percent) of the ISCVT cohort [<a href="#rid85">85</a>]. In this subgroup with early intracerebral hemorrhage, predictors of poor prognosis at six months were older age, male sex, thrombosis of the deep cerebral venous system or of the right lateral sinus, and a motor deficit [<a href="#rid85">85</a>].</p><p>By contrast, several studies have found that a good outcome after CVT is predicted when symptoms of intracranial hypertension are the only manifestations of CVT at the time of diagnosis [<a href="#rid46">46,86</a>]. In patients with CVT presenting with isolated intracranial hypertension, a subgroup analysis of the ISCVT cohort found that poor outcome was associated with a longer diagnostic delay [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H2354064714"><span class="h2">Recurrence</span><span class="headingEndMark"> — </span>The risk of recurrent CVT is approximately 2 to 4 percent, while the risk of recurrent venous thromboembolism (VTE) in other locations after CVT ranges from 4 to 7 percent. In the ISCVT study, which evaluated 624 patients with CVT over a median 16 months of follow-up, 14 (2 percent) had a recurrent CVT and 27 (4 percent) had other thrombotic events during follow-up [<a href="#rid15">15</a>]. The risks of recurrent CVT or any venous thrombosis were 1.5 and 4.1 per 100 person-years, respectively [<a href="#rid88">88</a>].</p><p>Observational data also suggest longer-term CVT recurrence rates appear to be lower than rates of recurrent VTE. In a retrospective cohort study of 706 patients with a first CVT who were followed for 6 to 297 months (median 40 months), CVT recurred in 31 patients (4 percent), and VTE in a different site occurred in 46 patients (7 percent) [<a href="#rid89">89</a>]. In another study that prospectively followed 145 patients with CVT for a median of six years after discontinuation of anticoagulant therapy, a recurrent CVT developed in five patients (3 percent), and other types of VTE developed in another 10 patients (6 percent) [<a href="#rid90">90</a>]. The risks of recurrent CVT or other types of VTE were 0.5 and 2.0 per 100 person-years, respectively.</p><p>Risk factors for CVT recurrence in adults include the following [<a href="#rid88">88-91</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of prior VTE</p><p class="bulletIndent1"><span class="glyph">●</span>Polycythemia/thrombocythemia</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical history or laboratory evidence of thrombophilia</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Black race</p><p></p><p>Data on CVT recurrence and risk factors in children are limited. In the European cohort of 396 children with CVT (median age five years) followed for a median of 36 months, recurrent venous thrombosis occurred in 22 children at a median of six months, including CVT in 13 children (3 percent) [<a href="#rid82">82</a>]. There were no recurrences of CVT among children younger than 25 months. Factors independently associated with recurrent cerebral and systemic venous thrombosis in children were nonadministration of anticoagulant therapy before relapse (hazard ratio [HR] 11.2, 95% CI 3.4-37.0), persistent occlusion on repeat venous imaging (HR 4.1, 95% CI 1.1-14.8), and heterozygosity for the prothrombin (factor II) <em>G20210A</em> variant (HR 4.3, 95% CI 1.1-16.2) [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H2595823051"><span class="h2">Recanalization</span><span class="headingEndMark"> — </span>Most patients with CVT achieve some degree of cerebral vein and sinus recanalization. A 2018 systematic review and meta-analysis identified 19 studies, mostly retrospective, that reported recanalization rates for adult patients with CVT who were treated with anticoagulation [<a href="#rid92">92</a>]. The overall recanalization rate was 85 percent among 818 patients who received follow-up imaging, with partial recanalization achieved by 35 percent and complete recanalization by 49 percent of patients. In the few studies with available data, the recanalization rate increased with time, and approximately three-quarters of patients had achieved recanalization at three months. Positive predictors of recanalization were thrombosis of the superior sagittal sinus and female sex; negative predictors of recanalization were multiple thromboses, hormonal therapy, older age, and lack of identified risk factors for CVT.</p><p>The meta-analysis also found that recanalization was associated with functional recovery [<a href="#rid92">92</a>]. A favorable outcome, defined as a modified Rankin Scale score  (<a class="graphic graphic_table graphicRef75411" href="/d/graphic/75411.html" rel="external">table 4</a>) of 0 (no symptoms) or 1 (no significant disability despite symptoms), was achieved in 319 of 357 (89 percent) patients with recanalization and in 42 of 59 (71 percent) patients without recanalization; the pooled odds ratio for a favorable outcome with recanalization was 3.3 (95% CI 1.2-8.9). In subsequent prospective cohort study of 68 patients with newly diagnosed CVT treated with anticoagulation and followed with MRI and magnetic resonance venography, early venous recanalization (confirmed by imaging on day 8 after starting anticoagulation) was associated with both regression and a reduced risk of enlargement of nonhemorrhagic lesions, including those with venous infarction [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2540536580"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112685.html" rel="external">"Society guideline links: Stroke in children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute anticoagulation </strong>– For adults with symptomatic cerebral venous thrombosis (CVT), with or without hemorrhagic venous infarction, we recommend initial anticoagulation therapy with subcutaneous low molecular weight heparin (LMWH) or intravenous heparin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). For children with CVT, with or without significant secondary hemorrhage, we suggest initial anticoagulation therapy with subcutaneous LMWH or intravenous heparin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial anticoagulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute complications </strong>– Complications that require intervention during the acute phase of CVT include elevated intracranial pressure, brain swelling, seizures, and infection. (See <a class="local">'Other acute management issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measures to control acutely increased intracranial pressure and impending herniation, including decompressive surgery, may be required in patients with CVT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CVT who have both seizures at presentation and focal cerebral supratentorial lesions (eg, edema, infarction, or hemorrhage on admission computed tomography or magnetic resonance imaging), we recommend seizure prophylaxis with an antiseizure medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2">For patients with a single early symptomatic seizure due to CVT in the absence of a supratentorial cerebral lesion, the benefit of seizure prophylaxis is uncertain due to low likelihood of recurrence. Seizure prophylaxis is <strong>avoided</strong> for those who have focal cerebral lesions without seizures. (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic treatment is mandatory whenever there is meningitis or other intracranial infection or an infection of a neighboring structure, such as otitis or mastoiditis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection and duration of anticoagulation </strong>– After the acute phase of CVT, we suggest anticoagulation for most patients with either a direct oral anticoagulant or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for 3 to 12 months (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Exceptions include patients with comorbid malignancy (for whom LMWH is preferred), antiphospholipid syndrome or chronic kidney disease (for whom warfarin is preferred), and those who are pregnant (for whom heparins are preferred). (See <a class="local">'Long-term anticoagulation'</a> above and <a class="local">'Selection of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent1">It is reasonable to continue anticoagulation for three to 6 months for patients with a provoked CVT associated with a transient risk factor  (<a class="graphic graphic_table graphicRef65303" href="/d/graphic/65303.html" rel="external">table 2</a>) and for 6 to 12 months for patients with an unprovoked CVT. Indefinite oral anticoagulation is reserved for patients with recurrent CVT, extracerebral venous thromboembolism after CVT, or those with an associated severe thrombophilia. (See <a class="local">'Duration of anticoagulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing the risk of recurrence </strong>– For pregnant patients with a history of CVT, we suggest temporary prophylactic anticoagulation with subcutaneous LMWH throughout pregnancy and continuing up to eight weeks postpartum (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For adolescent and adult females with a history of CVT, we advise <strong>not</strong> using combined oral contraceptives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– CVT is associated with a good outcome in close to 80 percent of patients. Approximately 5 percent of patients die in the acute phase of the disorder, and longer-term mortality is nearly 10 percent. The main cause of acute death with CVT is neurologic, most often from brain herniation. After the acute phase, most deaths are related to underlying disorders such as cancer. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484.</a></li><li><a class="nounderline abstract_t">Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand 1992; 86:390.</a></li><li><a class="nounderline abstract_t">Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nat Rev Neurol 2017; 13:555.</a></li><li><a class="nounderline abstract_t">Ferro JM, Aguiar de Sousa D. Cerebral Venous Thrombosis: an Update. Curr Neurol Neurosci Rep 2019; 19:74.</a></li><li><a class="nounderline abstract_t">Shlobin NA, LoPresti MA, Beestrum M, Lam S. Treatment of pediatric cerebral venous sinus thromboses: the role of anticoagulation. Childs Nerv Syst 2020; 36:2621.</a></li><li><a class="nounderline abstract_t">Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384:2124.</a></li><li><a class="nounderline abstract_t">Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021; 384:2092.</a></li><li><a class="nounderline abstract_t">Krzywicka K, van de Munckhof A, Sánchez van Kammen M, et al. Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology 2022; 98:e759.</a></li><li><a class="nounderline abstract_t">Krzywicka K, Heldner MR, Sánchez van Kammen M, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol 2021; 28:3656.</a></li><li><a class="nounderline abstract_t">Sánchez van Kammen M, Aguiar de Sousa D, Poli S, et al. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurol 2021; 78:1314.</a></li><li><a class="nounderline abstract_t">Pavord S, Scully M, Hunt BJ, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med 2021; 385:1680.</a></li><li><a class="nounderline abstract_t">Scutelnic A, Krzywicka K, Mbroh J, et al. Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination. Ann Neurol 2022; 92:562.</a></li><li><a class="nounderline abstract_t">Greinacher A, Langer F, Makris M, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20:149.</a></li><li><a class="nounderline abstract_t">Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.</a></li><li><a class="nounderline abstract_t">Ferro JM, Canhão P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664.</a></li><li><a class="nounderline abstract_t">Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597.</a></li><li><a class="nounderline abstract_t">Stam J, De Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2002; :CD002005.</a></li><li><a class="nounderline abstract_t">Misra UK, Kalita J, Chandra S, et al. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 2012; 19:1030.</a></li><li><a class="nounderline abstract_t">Coutinho JM, Ferro JM, Canhão P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 2010; 41:2575.</a></li><li><a class="nounderline abstract_t">Afshari D, Moradian N, Nasiri F, et al. The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis. Neurosciences (Riyadh) 2015; 20:357.</a></li><li><a class="nounderline abstract_t">Einhäupl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17:1229.</a></li><li><a class="nounderline abstract_t">Ferro JM, Correia M, Pontes C, et al. Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. Cerebrovasc Dis 2001; 11:177.</a></li><li><a class="nounderline abstract_t">Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis--a review of 38 cases. Stroke 1985; 16:199.</a></li><li><a class="nounderline abstract_t">Brucker AB, Vollert-Rogenhofer H, Wagner M, et al. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis 1998; 8:331.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction: factors affecting the initiation and safety of anticoagulation. Cerebrovasc Dis 1998; 8:25.</a></li><li><a class="nounderline abstract_t">deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417.</a></li><li><a class="nounderline abstract_t">Johnson MC, Parkerson N, Ward S, de Alarcon PA. Pediatric sinovenous thrombosis. J Pediatr Hematol Oncol 2003; 25:312.</a></li><li><a class="nounderline abstract_t">Sébire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005; 128:477.</a></li><li><a class="nounderline abstract_t">Schobess R, Düring C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006; 91:1701.</a></li><li><a class="nounderline abstract_t">Golomb MR. The risk of recurrent venous thromboembolism after paediatric cerebral sinovenous thrombosis. Lancet Neurol 2007; 6:573.</a></li><li><a class="nounderline abstract_t">Moharir MD, Shroff M, Stephens D, et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010; 67:590.</a></li><li><a class="nounderline abstract_t">Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8:e22.</a></li><li><a class="nounderline abstract_t">Siddiqui FM, Dandapat S, Banerjee C, et al. Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases. Stroke 2015; 46:1263.</a></li><li><a class="nounderline abstract_t">Coutinho JM, Zuurbier SM, Bousser MG, et al. Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis: The TO-ACT Randomized Clinical Trial. JAMA Neurol 2020; 77:966.</a></li><li><a class="nounderline abstract_t">Siddiqui FM, Weber MW, Dandapat S, et al. Endovascular Thrombolysis or Thrombectomy for Cerebral Venous Thrombosis: Study of Nationwide Inpatient Sample 2004-2014. J Stroke Cerebrovasc Dis 2019; 28:1440.</a></li><li><a class="nounderline abstract_t">Dentali F, Squizzato A, Gianni M, et al. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost 2010; 104:1055.</a></li><li><a class="nounderline abstract_t">Ferro JM, Bousser MG, Canhão P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24:1203.</a></li><li><a class="nounderline abstract_t">Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160.</a></li><li><a class="nounderline abstract_t">Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:1158.</a></li><li><a class="nounderline abstract_t">Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</a></li><li><a class="nounderline abstract_t">Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2019; 50:e51.</a></li><li><a class="nounderline abstract_t">Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.</a></li><li><a class="nounderline abstract_t">Raza E, Shamim MS, Wadiwala MF, et al. Decompressive surgery for malignant cerebral venous sinus thrombosis: a retrospective case series from Pakistan and comparative literature review. J Stroke Cerebrovasc Dis 2014; 23:e13.</a></li><li><a class="nounderline abstract_t">Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011; 42:2825.</a></li><li><a class="nounderline abstract_t">Lobo S, Ferro JM, Barinagarrementeria F, et al. Shunting in acute cerebral venous thrombosis: a systematic review. Cerebrovasc Dis 2014; 37:38.</a></li><li><a class="nounderline abstract_t">Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 1999; 53:1537.</a></li><li><a class="nounderline abstract_t">Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68:1528.</a></li><li><a class="nounderline abstract_t">Vidailhet M, Piette JC, Wechsler B, et al. Cerebral venous thrombosis in systemic lupus erythematosus. Stroke 1990; 21:1226.</a></li><li><a class="nounderline abstract_t">Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behçet's disease: a systematic review. J Neurol 2011; 258:719.</a></li><li><a class="nounderline abstract_t">Canhão P, Cortesão A, Cabral M, et al. Are steroids useful to treat cerebral venous thrombosis? Stroke 2008; 39:105.</a></li><li><a class="nounderline abstract_t">Ferro JM, Canhão P, Bousser MG, et al. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39:1152.</a></li><li><a class="nounderline abstract_t">Price M, Günther A, Kwan JS. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 2016; 4:CD005501.</a></li><li><a class="nounderline abstract_t">Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004; 21:639.</a></li><li><a class="nounderline abstract_t">Yaghi S, Saldanha IJ, Misquith C, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022; 53:3014.</a></li><li><a class="nounderline abstract_t">Ferro JM, Coutinho JM, Dentali F, et al. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol 2019; 76:1457.</a></li><li><a class="nounderline abstract_t">Yaghi S, Shu L, Bakradze E, et al. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022; 53:728.</a></li><li><a class="nounderline abstract_t">Connor P, Sánchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020; 4:6250.</a></li><li><a class="nounderline abstract_t">Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7:e18.</a></li><li><a class="nounderline abstract_t">Sánchez van Kammen M, Male C, Connor P, et al. Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis. Pediatr Neurol 2022; 128:20.</a></li><li><a class="nounderline abstract_t">Brandão LR, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood 2020; 135:491.</a></li><li><a class="nounderline abstract_t">Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.</a></li><li><a class="nounderline abstract_t">Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996; 27:243.</a></li><li><a class="nounderline abstract_t">Ferro JM, Correia M, Rosas MJ, et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003; 15:78.</a></li><li><a class="nounderline abstract_t">Sánchez van Kammen M, Lindgren E, Silvis SM, et al. Late seizures in cerebral venous thrombosis. Neurology 2020; 95:e1716.</a></li><li><a class="nounderline abstract_t">Bossoni AS, Peres MFP, Leite CDC, et al. Headache at the chronic stage of cerebral venous thrombosis. Cephalalgia 2022; 42:1476.</a></li><li><a class="nounderline abstract_t">Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60:1418.</a></li><li><a class="nounderline abstract_t">Higgins JN, Gillard JH, Owler BK, et al. MR venography in idiopathic intracranial hypertension: unappreciated and misunderstood. J Neurol Neurosurg Psychiatry 2004; 75:621.</a></li><li><a class="nounderline abstract_t">Higgins JN, Owler BK, Cousins C, Pickard JD. Venous sinus stenting for refractory benign intracranial hypertension. Lancet 2002; 359:228.</a></li><li><a class="nounderline abstract_t">Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.</a></li><li><a class="nounderline abstract_t">Tsumoto T, Miyamoto T, Shimizu M, et al. Restenosis of the sigmoid sinus after stenting for treatment of intracranial venous hypertension: case report. Neuroradiology 2003; 45:911.</a></li><li><a class="nounderline abstract_t">Ferro JM, Lopes MG, Rosas MJ, et al. Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis 2002; 13:272.</a></li><li><a class="nounderline abstract_t">Ferro JM, Canhão P, Bousser MG, et al. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke 2005; 36:1927.</a></li><li><a class="nounderline abstract_t">Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol 1995; 52:880.</a></li><li><a class="nounderline abstract_t">Acheson JF. Optic nerve disorders: role of canal and nerve sheath decompression surgery. Eye (Lond) 2004; 18:1169.</a></li><li><a class="nounderline abstract_t">de Bruijn SF, Budde M, Teunisse S, et al. Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis. Neurology 2000; 54:1687.</a></li><li><a class="nounderline abstract_t">Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol 2016; 263:477.</a></li><li><a class="nounderline abstract_t">Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:1545.</a></li><li><a class="nounderline abstract_t">Aguiar de Sousa D, Canhão P, Ferro JM. Safety of Pregnancy After Cerebral Venous Thrombosis: A Systematic Review. Stroke 2016; 47:713.</a></li><li><a class="nounderline abstract_t">Canhão P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005; 36:1720.</a></li><li><a class="nounderline abstract_t">Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43:262.</a></li><li><a class="nounderline abstract_t">Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke 2014; 45:1338.</a></li><li><a class="nounderline abstract_t">Kenet G, Kirkham F, Niederstadt T, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol 2007; 6:595.</a></li><li><a class="nounderline abstract_t">Ferro JM, Bacelar-Nicolau H, Rodrigues T, et al. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2009; 28:39.</a></li><li><a class="nounderline abstract_t">Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40:2356.</a></li><li><a class="nounderline abstract_t">Girot M, Ferro JM, Canhão P, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke 2007; 38:337.</a></li><li><a class="nounderline abstract_t">Gameiro J, Ferro JM, Canhão P, et al. Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis. Cephalalgia 2012; 32:407.</a></li><li><a class="nounderline abstract_t">Ferro JM, Canhão P, Stam J, et al. Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. Stroke 2009; 40:3133.</a></li><li><a class="nounderline abstract_t">Miranda B, Ferro JM, Canhão P, et al. Venous thromboembolic events after cerebral vein thrombosis. Stroke 2010; 41:1901.</a></li><li><a class="nounderline abstract_t">Dentali F, Poli D, Scoditti U, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10:1297.</a></li><li><a class="nounderline abstract_t">Martinelli I, Bucciarelli P, Passamonti SM, et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121:2740.</a></li><li><a class="nounderline abstract_t">Shu L, Bakradze E, Omran SS, et al. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study. Neurology 2022; 99:e2368.</a></li><li><a class="nounderline abstract_t">Aguiar de Sousa D, Lucas Neto L, Canhão P, Ferro JM. Recanalization in Cerebral Venous Thrombosis. Stroke 2018; 49:1828.</a></li><li><a class="nounderline abstract_t">Aguiar de Sousa D, Lucas Neto L, Arauz A, et al. Early Recanalization in Patients With Cerebral Venous Thrombosis Treated With Anticoagulation. Stroke 2020; 51:1174.</a></li></ol></div><div id="topicVersionRevision">Topic 1109 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066840" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1455986" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28820187" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31440838" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cerebral Venous Thrombosis: an Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32743709" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of pediatric cerebral venous sinus thromboses: the role of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33835768" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33835769" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34921101" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34293217" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581763" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379914" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35689346" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34693641" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315270" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976332" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1679154" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Heparin treatment in sinus venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519565" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anticoagulation for cerebral sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22416902" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930161" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492115" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402748" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306764" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3975957" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cerebral venous thrombosis--a review of 38 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774750" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645978" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cerebral venous thrombosis complicated by hemorrhagic infarction: factors affecting the initiation and safety of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496852" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cerebral sinovenous thrombosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679646" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pediatric sinovenous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699061" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145610" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582352" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The risk of recurrent venous thromboembolism after paediatric cerebral sinovenous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20437556" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33290737" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899238" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32421159" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis: The TO-ACT Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30952531" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endovascular Thrombolysis or Thrombectomy for Cerebral Venous Thrombosis: Study of Nationwide Inpatient Sample 2004-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20886189" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28833980" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24788967" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21293023" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315277" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30686119" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635845" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119368" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Decompressive surgery for malignant cerebral venous sinus thrombosis: a retrospective case series from Pakistan and comparative literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799156" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24356100" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Shunting in acute cerebral venous thrombosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534264" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Isolated intracranial hypertension as the only sign of cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420940" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2389304" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cerebral venous thrombosis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210139" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cerebral venous thrombosis in Behçet's disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063833" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Are steroids useful to treat cerebral venous thrombosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309177" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27098266" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15287823" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Poststroke epilepsy: epidemiology, pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35938419" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479105" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143325" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351120" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699660" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35032886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31805182" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315273" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8571417" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12499715" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Seizures in cerebral vein and dural sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759195" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Late seizures in cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35899769" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Headache at the chronic stage of cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743224" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15026510" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : MR venography in idiopathic intracranial hypertension: unappreciated and misunderstood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812561" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Venous sinus stenting for refractory benign intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12744365" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605788" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Restenosis of the sigmoid sinus after stenting for treatment of intracranial venous hypertension: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12011553" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100024" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cerebral vein and dural sinus thrombosis in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661725" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neuro-ophthalmic features of cerebral venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534602" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Optic nerve disorders: role of canal and nerve sheath decompression surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762517" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725090" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503673" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797665" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety of Pregnancy After Cerebral Venous Thrombosis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002765" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Causes and predictors of death in cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998058" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mortality of cerebral venous-sinus thrombosis in a large national sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24699058" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Declining mortality in cerebral venous thrombosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560171" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420921" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478226" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cerebral venous and sinus thrombosis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204682" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407654" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608994" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634477" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Venous thromboembolic events after cerebral vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578023" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547928" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36123126" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021808" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Recanalization in Cerebral Venous Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32114929" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Early Recanalization in Patients With Cerebral Venous Thrombosis Treated With Anticoagulation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
